Closing of Initial Public Offering

IRadimed Corporation Announces Closing of Initial Public Offering.

IRADIMED CORPORATION (NASDAQ:IRMD), the leading provider of non-magnetic intravenous (IV) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures, announced that it has closed its initial public offering of 2,318,400 shares of common stock at a price of $6.25 per share, including 302,400 shares sold pursuant to the over-allotment option exercised in full by the underwriters of the initial public offering. Shares began trading on the NASDAQ Capital Market under the symbol IRMD on July 16, 2014.

Roth Capital Partners is acting as sole book-running manager for the offering and Monarch Capital Group is acting as co-manager.

The common stock was issued pursuant to a registration statement on Form S-1, which was declared effective by the Securities and Exchange Commission on July 15, 2014. Copies of the written prospectus for the offering may be accessed through the Securities and Exchange Commission's website at, or may be obtained from Roth Capital Partners, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660,

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


IRADIMED CORPORATION is the leading provider of non-magnetic IV infusion pump systems that are safe for use during MRI procedures. Electromechanical medical devices and pumps contain magnetic and electronic parts which generate radio frequency noise, create interference and are dangerous to operate in the presence of the powerful magnet which drives an MRI. The company's mRidium™ (3850+3860+) IV pump systems have been designed with non-ferrous parts, ceramic ultrasonic motors, non-magnetic mobile stand and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. The company's pump solution provides a seamless approach to providing IV fluids before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants must generally be sedated in order to remain immobile during an MRI scan. For more information please visit
mRidium™ is a trademark of IRADIMED CORPORATION.

Kevin Jirka